<p>芝加哥 --（商业资讯）--Cresco Labs Inc.（CSE: CL）（OTCQX: CRLBF）（FSE: 6CQ）（“Cresco Labs” 或 “公司”）今天发布了 Cresco Labs 首席执行官 Charlie Bachtell 的声明，回应特朗普总统将大麻从《受控物质法》第一类物质重新分类为第三类物质的行动。</p>
<p><em>“今天标志着美国大麻历史上最重要的时刻。将大麻从第一类物质转为第三类物质的决定将成为一个文化转折点，承认数百万美国人已经知道的事实：大麻是药物，值得负责任和常识的监管。”</em></p>
<p><em>“这一行动开始弥合联邦法律与美国人民意愿之间的差距，近 90% 的美国人支持某种形式的大麻合法化，74% 的人已经生活在合法大麻的州。重新分类为第三类物质为全面的医学研究解锁了机会。它验证了那些为其选民开创深思熟虑、高度监管的大麻项目的州领导者的工作。它向我们的刑事司法系统发出了强烈的信息，要求停止因一种已经被用作药物超过 5000 年的植物而监禁人们。”</em></p>
<p><em>“对于估计有 45 万人在受监管的大麻行业工作来说，重新分类是第一块多米诺骨牌，铺平了大麻被正常化、受到尊重并最终像其他美国行业一样对待的道路。这将消除大麻公司的不公平税负，使运营商能够在我们服务的社区中重新投资于新的基础设施和就业增长。它还为银行改革和进入美国资本市场的进展奠定了必要的基础，这是将联邦政策与这一行业的规模和复杂性对齐的关键步骤。”</em></p>
<p><em>“我们赞扬特朗普总统的这一行动，并继续致力于建立这个国家应有的负责任、受尊重和强大的大麻行业。”</em></p>
<p><strong>关于 Cresco Labs Inc.</strong></p>
<p>Cresco Labs 的使命是通过以消费者为中心的零售体验和建立国家品牌的 CPG 方法，使医疗大麻行业正常化和专业化，同时在立法和监管倡议上充当行业的管理者。作为种植、生产和品牌产品分销的领导者，公司正在利用其规模和灵活性，在全国范围内扩大其包括 Cresco、High Supply、FloraCal、Good News、Wonder Wellness Co.、Mindy’s 和 Remedi 在内的品牌组合。公司还在全国范围内以 Sunnyside 品牌运营高效的药房，专注于建立患者和消费者的信任，并在传统零售体验中提供持续的教育和便利。通过全年政策、社区外展和 SEED 倡议的努力，Cresco Labs 承担着通过真实参与、经济机会、投资、劳动力发展和旨在创造最负责任、受尊重和强大的医疗大麻行业的立法倡议来支持社区的责任。通过访问 www.crescolabs.com 或在 Facebook、X 或 LinkedIn 上关注公司，了解 Cresco Labs 的旅程。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含适用的加拿大证券立法下的 “前瞻性信息”，也可能包含根据 1995 年美国私人证券诉讼改革法的安全港条款构成的 “前瞻性声明”（统称为 “前瞻性声明”）。此类前瞻性声明并不代表历史事实或信息或当前状况，而仅代表公司对未来事件、计划或目标的信念，其中许多本质上是不确定的，并且超出了公司的控制范围。通常，此类前瞻性声明可以通过使用前瞻性术语来识别，例如 “可能”、“将”、“应该”、“可以”、“会”、“期望”、“计划”、“预期”、“相信”、“估计”、“项目”、“预测”、“潜在” 或 “继续” 或这些形式的否定或其他可比术语。公司的前瞻性声明涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致公司的实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就有重大不同，包括但不限于在公司截至 2024 年 12 月 31 日的年度信息表中讨论的 “风险因素”，该表已在 SEDAR+ 和 EDGAR 上提交，以及公司向加拿大证券监管机构提交的其他文件；以及许多超出公司控制范围的其他因素。读者应注意，以上因素的列表并不详尽。由于这些不确定性，您不应对公司的前瞻性声明过于依赖。对于 Cresco Labs 股票未来的交易价格或交易量，以及公司在未来财务期间的财务表现，均不提供任何保证。公司不打算更新任何这些因素或公开宣布对本声明中包含的任何前瞻性声明的任何修订结果，无论是由于新信息、任何未来事件还是其他原因。除非另有说明，本新闻稿的内容截至本日期。发布本新闻稿并不意味着在本日期后公司的事务没有变化，也不构成更新或补充本新闻稿中提供的任何信息的义务或承诺。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTc4NTU3OTlyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTc4NTU3OTlyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251217855799/en/</p>
<p><strong>媒体</strong></p>
<p>press@crescolabs.com</p>
<p><strong>投资者</strong></p>
<p>investors@crescolabs.com</p>
<p><em>有关 Cresco Labs 的一般咨询：</em></p>
<p>312-929-0993</p>
<p>info@crescolabs.com</p>
<p>来源：Cresco Labs</p>

CRLBF

<p>Cresco Labs 首席执行官 Charlie Bachtell 称赞特朗普总统将大麻从第一类药物重新分类为第三类药物的决定，认为这是该行业的历史性转变。这一变化承认了大麻作为药物的地位，使联邦法律与公众舆论相一致，并为医学研究和行业增长打开了机会。它还解决了税负和银行改革的问题，为大麻的正常化和进入资本市场铺平了道路。Cresco Labs 旨在建立一个负责任且强大的大麻行业</p>

<p>CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today issued a statement on behalf of Cresco Labs CEO Charlie Bachtell following President Trump’s action to reschedule cannabis from a Schedule I to Schedule III substance under the Controlled Substances Act.</p>
<div class="lb-trans"><p>芝加哥 --（商业资讯）--Cresco Labs Inc.（CSE: CL）（OTCQX: CRLBF）（FSE: 6CQ）（“Cresco Labs” 或 “公司”）今天发布了 Cresco Labs 首席执行官 Charlie Bachtell 的声明，回应特朗普总统将大麻从《受控物质法》第一类物质重新分类为第三类物质的行动。</p>
</div><p><em>“Today marks the most consequential moment in the history of U.S. cannabis. The decision to move cannabis from Schedule I to Schedule III will be a cultural turning point, acknowledging what millions of Americans already know: cannabis is medicine and deserves responsible, common-sense regulation.</em></p>
<div class="lb-trans"><p><em>“今天标志着美国大麻历史上最重要的时刻。将大麻从第一类物质转为第三类物质的决定将成为一个文化转折点，承认数百万美国人已经知道的事实：大麻是药物，值得负责任和常识的监管。”</em></p>
</div><p><em>This action starts bridging the gap between federal law and the will of the American people, with nearly 90 percent of Americans supporting some form of cannabis legalization and 74 percent already living in states with legal cannabis. Rescheduling unlocks opportunities for comprehensive medical research. It validates the work of state leaders who pioneered thoughtful, highly regulated cannabis programs for their constituents. It sends a strong message to our criminal justice system to stop imprisoning people for a plant that’s been used as medicine for more than 5,000 years.</em></p>
<div class="lb-trans"><p><em>“这一行动开始弥合联邦法律与美国人民意愿之间的差距，近 90% 的美国人支持某种形式的大麻合法化，74% 的人已经生活在合法大麻的州。重新分类为第三类物质为全面的医学研究解锁了机会。它验证了那些为其选民开创深思熟虑、高度监管的大麻项目的州领导者的工作。它向我们的刑事司法系统发出了强烈的信息，要求停止因一种已经被用作药物超过 5000 年的植物而监禁人们。”</em></p>
</div><p><em>For the estimated 450,000 people working in the regulated cannabis industry, rescheduling is the first domino to fall, paving the way for cannabis to be normalized, respected and finally treated like any other U.S. industry. It will remove cannabis companies’ unfair tax burden, allowing operators to reinvest in new infrastructure and job growth in the communities we serve.</em> <em>It also lays essential groundwork for progress on banking reform and access to U.S. capital markets, critical steps toward aligning federal policy with the scale and sophistication of this industry.</em></p>
<div class="lb-trans"><p><em>“对于估计有 45 万人在受监管的大麻行业工作来说，重新分类是第一块多米诺骨牌，铺平了大麻被正常化、受到尊重并最终像其他美国行业一样对待的道路。这将消除大麻公司的不公平税负，使运营商能够在我们服务的社区中重新投资于新的基础设施和就业增长。它还为银行改革和进入美国资本市场的进展奠定了必要的基础，这是将联邦政策与这一行业的规模和复杂性对齐的关键步骤。”</em></p>
</div><p><em>We commend President Trump for this action and remain committed to building the responsible, respectable and robust cannabis industry this country deserves.”</em></p>
<div class="lb-trans"><p><em>“我们赞扬特朗普总统的这一行动，并继续致力于建立这个国家应有的负责任、受尊重和强大的大麻行业。”</em></p>
</div><p><strong>About Cresco Labs Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Cresco Labs Inc.</strong></p>
</div><p>Cresco Labs’ mission is to normalize and professionalize the medical marijuana industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust medical marijuana industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.</p>
<div class="lb-trans"><p>Cresco Labs 的使命是通过以消费者为中心的零售体验和建立国家品牌的 CPG 方法，使医疗大麻行业正常化和专业化，同时在立法和监管倡议上充当行业的管理者。作为种植、生产和品牌产品分销的领导者，公司正在利用其规模和灵活性，在全国范围内扩大其包括 Cresco、High Supply、FloraCal、Good News、Wonder Wellness Co.、Mindy’s 和 Remedi 在内的品牌组合。公司还在全国范围内以 Sunnyside 品牌运营高效的药房，专注于建立患者和消费者的信任，并在传统零售体验中提供持续的教育和便利。通过全年政策、社区外展和 SEED 倡议的努力，Cresco Labs 承担着通过真实参与、经济机会、投资、劳动力发展和旨在创造最负责任、受尊重和强大的医疗大麻行业的立法倡议来支持社区的责任。通过访问 www.crescolabs.com 或在 Facebook、X 或 LinkedIn 上关注公司，了解 Cresco Labs 的旅程。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.</p>
<div class="lb-trans"><p>本新闻稿包含适用的加拿大证券立法下的 “前瞻性信息”，也可能包含根据 1995 年美国私人证券诉讼改革法的安全港条款构成的 “前瞻性声明”（统称为 “前瞻性声明”）。此类前瞻性声明并不代表历史事实或信息或当前状况，而仅代表公司对未来事件、计划或目标的信念，其中许多本质上是不确定的，并且超出了公司的控制范围。通常，此类前瞻性声明可以通过使用前瞻性术语来识别，例如 “可能”、“将”、“应该”、“可以”、“会”、“期望”、“计划”、“预期”、“相信”、“估计”、“项目”、“预测”、“潜在” 或 “继续” 或这些形式的否定或其他可比术语。公司的前瞻性声明涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致公司的实际结果、表现或成就与前瞻性声明所表达或暗示的任何未来结果、表现或成就有重大不同，包括但不限于在公司截至 2024 年 12 月 31 日的年度信息表中讨论的 “风险因素”，该表已在 SEDAR+ 和 EDGAR 上提交，以及公司向加拿大证券监管机构提交的其他文件；以及许多超出公司控制范围的其他因素。读者应注意，以上因素的列表并不详尽。由于这些不确定性，您不应对公司的前瞻性声明过于依赖。对于 Cresco Labs 股票未来的交易价格或交易量，以及公司在未来财务期间的财务表现，均不提供任何保证。公司不打算更新任何这些因素或公开宣布对本声明中包含的任何前瞻性声明的任何修订结果，无论是由于新信息、任何未来事件还是其他原因。除非另有说明，本新闻稿的内容截至本日期。发布本新闻稿并不意味着在本日期后公司的事务没有变化，也不构成更新或补充本新闻稿中提供的任何信息的义务或承诺。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTc4NTU3OTlyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251217855799r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251217855799/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20251217855799/en/</p>
</div><p><strong>Media</strong></p>
<div class="lb-trans"><p><strong>媒体</strong></p>
</div><p>press@crescolabs.com</p>
<div class="lb-trans"><p>press@crescolabs.com</p>
</div><p><strong>Investors</strong></p>
<div class="lb-trans"><p><strong>投资者</strong></p>
</div><p>investors@crescolabs.com</p>
<div class="lb-trans"><p>investors@crescolabs.com</p>
</div><p><em>For general Cresco Labs inquiries:</em></p>
<div class="lb-trans"><p><em>有关 Cresco Labs 的一般咨询：</em></p>
</div><p>312-929-0993</p>
<div class="lb-trans"><p>312-929-0993</p>
</div><p>info@crescolabs.com</p>
<div class="lb-trans"><p>info@crescolabs.com</p>
</div><p>Source: Cresco Labs</p>
<div class="lb-trans"><p>来源：Cresco Labs</p>
</div>

Cresco Labs 首席执行官表示：重新安排标志着大麻行业的历史性转变 | CRLBF 股票新闻